⌘+K

News

Better-than-feared Q4 overshadowed by cautious outlook

Erik Hultgård

Arvid Necander

2026-05-08

09:10 CEST

Q4 was somewhat better than feared on an underlying basis, but we expect focus to centre on the softer-than-expected 2026/27 guidance, where limited visibility, elevated leverage and a muted near-term outlook are likely to weigh on sentiment.

As we had expected, EQL reported a soft Q4 2025/26, largely owing to scrapping and elevated freight costs. Sales increased 6% Y/Y to SEK120m (3% above DCARe), while EBIT declined 78% Y/Y to SEK5m (57% below DCARe). Adjusting for items not included in our forecast (mainly write-downs and antibiotic clearance sales), which reduced the gross margin to 28%, EBIT was c.20% above our estimate. The company reported NRIs of SEK13m, although we had already included c. SEK4m related to scrapping and higher freight costs in our unadjusted estimate, as the company has historically taken a relatively conservative approach to adjustments. Inventory levels improved further versus Q3, although some deliveries remain pending.

Focus is likely to be on the newly issued 2026/27 guidance, where our cautious stance on the shares ahead of the numbers appears justified. The company is guiding for a muted near-term outlook, citing challenging logistics and geopolitical uncertainty, with expected sales growth of 15% (vs DCARe at 30%; consensus not available) and no explicit margin guidance. Visibility remains limited, as the assumptions underpinning the outlook remain unclear, with management noting the forecast is based on the current situation and will be refined continuously.

Long-term financial targets are intact, with a sales CAGR of 30% over 2024/25–28/29e and an EBITDA margin above 25% by the end of the period. The pipeline stood at 44 products in the quarter (vs 47 in Q3), reflecting two additions and the removal of seven candidates deemed to have limited long-term potential. While this still suggests plenty of growth fuel remains, we expect the soft near-term guidance, elevated leverage (currently 5.0x EBITDA) – which is likely to remain high through much of 2026/27e, and limited visibility to weigh on the shares today.

Sweden

Healthcare

Latest share price

SEK

23.2

-4.13%

18 Nov 2026 15:41 CET

Fair value range

SEK

35.0

—

55.0

30 Oct 2026

Market cap

SEK

678

m

Key stats

Year

2026e

EPS

0.30

EPS (Adj.)

1.48

Sales Growth

17.51%

EPS Growth (Adj.)

71.52%

P/E

77.0

P/E (Adj.)

15.5

EV/EBITA

26.7

EV/EBITDA

15.2

Learn more

About DNB Carnegie Access

DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

Private Banking

Tailored wealth management. Your financial future, personalized.

Montrose

A digital investment platform designed for passionate investors.

DNB Carnegie

Leading Nordic investment bank and wealth management.

© Copyright DNB Carnegie Investment Bank AB